Research
Hormonal
Semaglutide is endorsed for obesity treatment following its FDA approval for type 2 diabetes.
Health practitioners can consider semaglutide as a treatment option for obesity.
StrongSupportsmedium confidence
semaglutide, a ground-breaking GLP-1 agonist, takes the spotlight, tracing its journey from FDA approval for type 2 diabetes to its recent endorsement for obesity.
Why this rating
The claim is based on regulatory approval information.
Source
Semaglutide (Ozempic) and obesity. A comprehensive guide for aestheticians
Vasiliki-Sofia Grech et al. · Review of Clinical Pharmacology and Pharmacokinetics - International Edition · 2024
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →